Cost Effectiveness and Resource Allocation is a premier open-access journal published by BMC, dedicated to advancing the field of health policy and economics. Since its inception in 2003, the journal has provided a platform for researchers, policymakers, and healthcare professionals to disseminate crucial findings and insights relevant to cost-effectiveness analyses and resource allocation strategies. With an increasing impact factor and ranking within the Q2 category of health policy journals, it ranks #138 out of 310 in Scopus, placing it in the 55th percentile among its peers. The journal aims to facilitate knowledge exchange that can transform health policy and improve healthcare delivery through rigorous research, evaluation, and dialogue. Open access since its establishment, it ensures that critical findings are available to a global audience, thereby enhancing the impact and reach of its published works.

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE is a leading academic journal published by Cambridge University Press, specializing in the critical evaluation of healthcare technologies and their impact on health policy. Established in 1970, it has gained recognition within the field, currently holding a prestigious Q2 ranking in Health Policy, with a commendable position of #89 out of 310 in the Scopus rankings, placing it in the 71st percentile. The journal serves as an essential platform for researchers, professionals, and students interested in the intersection of technology and health care, facilitating the dissemination of innovative research findings and practical assessments that inform policy-making and improve health outcomes. With a focus on advancing knowledge from 1985 to 2024, the journal's content remains relevant and impactful. Though not open access, it offers subscription-based access to a wealth of articles that contribute to shaping the future of healthcare technology assessment.

Circulation-Cardiovascular Quality and Outcomes, published by LIPPINCOTT WILLIAMS & WILKINS, stands as a leading journal in the field of cardiology and cardiovascular medicine, boasting an impressive impact factor and ranking in the Q1 category for both Cardiology and Cardiovascular Medicine, as well as in the broader field of Medicine (miscellaneous) as of 2023. With a dedicated focus on enhancing cardiovascular health through high-quality research, this journal disseminates vital findings that address clinical practice, healthcare delivery, and policy improvements. Operating under a rigorous peer-review process, it offers a platform for innovative studies and evidence-based insights essential for researchers, healthcare professionals, and students committed to advancing cardiovascular care. Although not an open-access journal, its contributions are invaluable to the ongoing dialogue within the medical community, driving essential changes and advancements in cardiovascular outcomes.

HEALTH TECHNOLOGY ASSESSMENT is a prestigious open-access journal published by the NIHR Journals Library, focusing on advancing the science of health technology assessment through robust research and critical analysis in the fields of Health Policy and Medicine. Since its inception in 2001, this journal has fostered a multidisciplinary approach to evaluating health technologies, offering invaluable insights to researchers, healthcare professionals, and policymakers. With an impressive Q1 ranking in both Health Policy and Medicine (miscellaneous) for 2023, it stands at the forefront of academic discourse, reflecting a high-impact factor and an esteemed reputation within its respective categories. The journal not only publishes original research articles, but also reviews and case studies that illuminate the complexities of health technology in real-world applications. Established and based in the United Kingdom, HEALTH TECHNOLOGY ASSESSMENT strives to encourage evidence-based decision-making, making it an essential resource for anyone committed to enhancing healthcare outcomes through innovative technology assessments.

Pharmacoeconomics-Open, an esteemed journal published by SPRINGER INT PUBL AG, is a vital resource for scholars and practitioners in the fields of health policy and pharmacology. Since its transition to an Open Access platform in 2017, the journal has aimed to democratize access to valuable research, fostering innovation and collaboration globally. With notable rankings in the 2023 Scopus indices—including Q2 in Health Policy and both categories of Pharmacology—Pharmacoeconomics-Open engages with pressing issues in health economics, providing insights into cost-effectiveness analyses and healthcare decision-making. The journal’s commitment to high-quality, peer-reviewed articles ensures that it remains a significant player in advancing knowledge and understanding within its disciplines, serving as an essential forum for researchers, policymakers, and students alike.

Health Economics Review is a premier, peer-reviewed journal dedicated to advancing knowledge and research in the dynamic field of health economics and policy. Published by BMC, this Open Access journal has been a vital resource since 2011, providing a platform for scholars and practitioners to share their findings and insights on pressing health policy issues. With an impressive Q2 ranking in the Health Policy category and a Scopus rank of 113 out of 310, it reflects a solid standing within the academic community, capturing a 63rd percentile ranking that underscores its contribution to the field. The journal covers an extensive range of topics including health systems, economic evaluations, and policy analysis, making it essential reading for researchers, health professionals, and policymakers. Located in Germany, with an operational address at CAMPUS, 4 Crinan St, London, the journal is committed to fostering innovation and collaboration in health economics, thereby shaping a healthier future for all.

Expert Opinion on Orphan Drugs is a pivotal academic journal published by Taylor & Francis Ltd, focusing on the burgeoning field of orphan drugs, which are often essential for treating rare diseases. As an integral source of insights and advancements from 2013 to 2024, this journal aims to bridge the gap between emerging scientific research and clinical application, providing a platform for authors to discuss pharmacological innovations and policy implications. With its ISSN 2167-8707, the journal has established a reputably rigorous editorial process and is indexed in Scopus, showcasing its relevance with ranks in various pharmacology and health policy disciplines. Though currently not an open-access journal, it endeavors to deliver high-quality articles that are vital for researchers, healthcare professionals, and policy makers aiming to navigate the complexities and challenges in the orphan drug landscape. It is categorized in Q4 for Health Policy and Q3 for Pharmacology in recent evaluations, reflecting its accessible yet scholarly contributions to this niche area of medical research.

Pragmatic and Observational Research, published by DOVE MEDICAL PRESS LTD, is a distinguished open-access journal that has been advancing knowledge in the fields of clinical practices and epidemiological studies since its inception in 2010. With an ISSN of 1179-7266, this journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality research that influences real-world health outcomes. Although the journal does not currently have an HIndex or Scopus ranking, its commitment to open access ensures that all articles are readily available to a global audience, facilitating broad engagement and collaboration. The journal focuses on pragmatic and observational methodologies, emphasizing studies that inform evidence-based practices in health care, thereby playing a crucial role in aligning research with practical health challenges. By contributing to the understanding of health interventions and observational data, Pragmatic and Observational Research continues to uphold its mission of improving health care through rigorous research.

PHARMACOECONOMICS, published by ADIS INT LTD, is a prestigious international journal dedicated to disseminating research in the fields of health policy, pharmacology, and public health. With an impressive impact factor and a solid Q1 ranking across its relevant categories, this journal plays a crucial role in shaping policy decisions, optimizing health resources, and enhancing pharmacoeconomic evaluations globally. The journal not only targets researchers and professionals but also serves as an invaluable resource for students striving to understand the economic implications of pharmaceutical care. Operating since 1992 and continuously evolving through 2024, PHARMACOECONOMICS invites contributions that address the complexities of drug expenditure, health outcomes, and public health implications, thereby fostering informed decision-making in healthcare systems. Readers can explore cutting-edge studies and analyses aimed at balancing cost-effectiveness with clinical effectiveness, making this journal a cornerstone for stakeholders invested in the future of health economics.

Welcome to the Journal of Evidence Based Medicine, a premier platform dedicated to advancing the field of health policy and medicine through rigorous research and scholarship. Published by WILEY, this esteemed journal, with an ISSN of 1756-5383 and E-ISSN 1756-5391, is headquartered in the United Kingdom and serves as a pivotal resource for disseminating high-quality evidence-based research. Operating within the converged years from 2008 to 2024, the journal boasts a remarkable standing, achieving a Q1 category ranking in both Health Policy and Medicine (Miscellaneous) for 2023, and ranking #12 out of 310 in the Scopus Ranks for Medicine & Health Policy, placing it in the 96th percentile. This commitment to excellence makes the journal a significant conduit for professionals, researchers, and students who seek to inform their practices with the latest evidence and foster advancements in health policy and medical practice. While currently not open access, the journal maintains a rigorous selection process to ensure the highest standards of publication, appealing to anyone intent on exploring groundbreaking studies that shape the health landscape globally.